Vaccine Management Analytics: Will It Be The Next 2021 Data Story?

As the world enters the second year of the coronavirus pandemic, actionable insights are more critical than ever. They’re even being prioritized in the new National Strategy for COVID-19 Response and Pandemic Preparedness alongside executive orders to evaluate progress, monitor outcomes, and support transparency and equity with Americans.

As the world rolls out COVID-19 vaccines, the need for accurate and timely vaccination distribution and uptake data is top-of-mind for government leaders, public health organizations, and healthcare providers everywhere. These metrics are foundational for managing vaccination programs, measuring their effectiveness, and determining our collective progress toward “a blanket of herd immunity,” as described by Dr. Anthony Fauci, director, National Institute of Allergy and Infectious Diseases and chief medical advisor for the Biden Administration.

This is a “wartime effort,” as we’ve heard national leaders state recently, to protect population health—particularly the most vulnerable—as well as to contain the virus as we lower case counts toward zero and to restore Americans’ trust with different discourse. By creating public performance dashboards for more transparency and accountability, and prioritizing a data-driven approach in the efforts and decisions of federal, state and local governments, vaccine management analytics is already the data story of 2021.

Vaccine Management Analytics In The Spotlight

Effective management of any vaccine distribution program requires a holistic picture of the vaccine supply chain, the populations being prioritized, the success rate in reaching those populations, and the strengths and weaknesses of the metrics used to measure progress and performance.

On the path to recovery, government leaders, the public and private sector, and healthcare providers have realized that vaccine administration and management is a complex, evolving process. Expecting we could implement it overnight with a one-size-fits-all approach was unrealistic—some may say foolish—and we must ask some of these important questions as we press forward:

  • Where is the greatest vaccine reluctance based on rate of spread and case count?
  • How do we prioritize population groups for immunization and maintain equity?
  • What level of awareness and understanding exists around vaccine safety and efficacy?
  • How does vaccine supply match demand?
  • In which direction are immunizations tracking and impacting COVID spread?
  • Are vaccine sites known and sufficiently equipped and staffed?

As we create the path to normalcy, with increased access, use and communication with data and analytics, we can elevate our national and local pandemic response and make better vaccine management decisions that have a national and global impact.

For several months, I’ve conversed with government leaders and health officials, considering their concerns and questions and discussing how data analytics can assuage them. With those engagements top-of-mind, I’d like to highlight:

  • Some effective vaccine management dashboard examples that states are leveraging for their needs and situations
  • How some states are using data and analytics to achieve positive outcomes

Using Data To Guide COVID-19 Vaccine Management

Furthermore, with increased plans to expand vaccine manufacturing and purchases, and improve national allocation, distribution, administration and tracking, there will be more data for government leaders to capture, monitor and share for a clearer sense of how localized efforts impact national goals, benchmarks and reporting.

The national vaccine effort is one of the greatest operational challenges America has faced. As we prioritize data and visual analytics in our response and resolution, our learnings can help frame how we approach future events and crises. The dashboard examples that I’ll share, containing sample data, demonstrate how data informs vaccine management, but the same analytics principles and approach could be applied to management of other national challenges.

Tracking Performance Against Vaccine Goals

Do you need to pivot local attention to track down more vaccines or other treatment supplies? Are mortality rates on the rise, unexpectedly? Is there a certain community that needs increased attention? Do we need additional marketing and public outreach to overcome vaccine reluctance and hesitancy? These questions and more are weighing on the minds and hearts of our leaders and public health officials and can be explored through solutions like a performance management dashboard, shown below.

By tracking performance in this way, it’s easier to take a snapshot of local progress to see if a state will meet, exceed or fall short of vaccine goals. It is also an effective communication tool for governors, mayors or county executives to be transparent with constituents and the public in their briefings and updates…….Read more

By:  Srinivas Kosaraju, Senior Director, Public Sector, Solution Engineers, Tableau Software

Source: Vaccine Management Analytics: Will It Be The Next 2021 Data Story?

.

 

CanSino’s COVID-19 Vaccine Candidate Approved For Military Use In China

1

FILE PHOTO: Small bottles labeled with a “Vaccine COVID-19” sticker and a medical syringe are seen in this illustration taken taken April 10, 2020. REUTERS/Dado Ruvic/File Photo

BEIJING (Reuters) – China’s military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics (6185.HK) after clinical trials proved it was safe and showed some efficacy, the company said on Monday.

The Ad5-nCoV is one of China’s eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the new coronavirus. The shot also won approval for human testing in Canada.

China’s Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing. The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS).

“The Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department,” CanSino said, referring to the Central Military Commission department which approved the military use of the vaccine.

CanSino declined to disclose whether the innoculation of the vaccine candidate is mandatory or optional, citing commercial secrets, in an email to Reuters.

The military approval follows China’s decision earlier this month to offer two other vaccine candidates to employees at state-owned firms travelling overseas.

The Phase 1 and 2 clinical trials of the CanSino’s vaccine candidate showed it has the potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success cannot be guaranteed, the company said.

Separately, AMS received an approval earlier this month to test its second experimental coronavirus vaccine in humans.

No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Ana Nicolaci da Costa

728x90

785K subscribers
CanSino Biologics, a Chinese company developing a COVID-19 vaccine with the help of some Canadian scientists, saw some early success in the first phase of clinical trials. Welcome to The National, the flagship nightly newscast of CBC News. »»» Subscribe to The National to watch more videos here: https://www.youtube.com/user/CBCTheNa… Voice your opinion and connect with us online: